Trial Profile
A Phase III Non-comparative Open-label Clinical Study to Evaluate the Response to and Safety of Kuvan (Sapropterin Dihydrochloride) After 6 Weeks of Treatment in Patients of 4 to 18 Years of Age With Phenylketonuria Who Have Elevated Blood Phenylalanine Levels
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Dec 2018
Price :
$35
*
At a glance
- Drugs Sapropterin (Primary)
- Indications Phenylketonuria
- Focus Therapeutic Use
- Sponsors Merck KGaA
- 18 Nov 2014 New trial record